CATEGORY

Biomarkers

Assays to evaluate presence or progress of a disease.

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Biomarkers.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo

Biomarkers Market Monitoring Dashboard


Supply Demand

Understand the correlation between costs, margins, and prices impacting your category on a real time basis on Beroe LiVE.Ai™

Biomarkers Industry Benchmarks


Savings Achieved

(in %)

The average annual savings achieved in Biomarkers category is 5.40%

Payment Terms

(in days)

The industry average payment terms in Biomarkers category for the current quarter is 73.4 days

Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™

Category Strategy and Flexibility

Engagement Model

Supply Assurance

Sourcing Process

Supplier Type

Pricing Model

Contract Length

SLAs/KPIs

Lead Time

Supplier Diversity

Targeted Savings

Risk Mitigation

Financial Risk

Sanctions

AMEs

Geopolitical Risk

Cost Optimization

Price per Unit Competitiveness

Specification Leanness

Minimum Order Quality

Payment Terms

Inventory Control

Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Biomarkers Suppliers


    4,017
    Total Suppliers
    169
    Diverse Suppliers
    73
    Normalized Supplier Rating
    Biomarkers Supplier

    Find the right-fit biomarkers supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    36

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77

    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Biomarkers market frequently asked questions


    As per Beroe, the primary factors that drive the growth of the biomarkers market are: Increasing diagnostic applications of biomarkers Rise in R&D funding from the government Growing number of CROs Low cost of clinical trials in the developing countries High prevalence and incidence of chronic diseases New initiatives for biomarker research

    The main uses of the biomarkers within the industry are: Predicting the prognosis and selecting dose regimes Detecting therapeutic advances and adverse responses For patient satisfaction based on efficacy or safety prediction They can also help to select appropriate patients for treatment with certain drugs, hence enables personalized medicine

    According to Beroe's insights, the genomics-based biomarker platform is the fastest growing and heavily adopted technology.

    As per Beroe, the genomics biomarker market is expected to grow at a CAGR of nearly 25 ' 26 percent, while for proteomics and imaging biomarkers, the growth rate is anticipated around 12 ' 14 percent and 14 ' 15 percent respectively in the next five years.

    The cancer biomarkers market is estimated to grow at a CAGR of 15 ' 15.5 percent and its market share is expected to reach a valuation of $32,632.11 million by 2024.

    As per Beroe's study, the core factors that drive the growth of the cancer biomarkers market include: An increasing rate of cancer patients Technological advancements of omics Need for personalized cancer treatments The rise in government funding for cancer research

    Cardiovascular disorders are expected to grow at the highest CAGR of 15.9 percent to reach a valuation of $25,063.53 by 2024.

    Cardiac biomarkers are majorly used as risk stratification for various CVDs like myocardial infarction, congestive heart failure, ACS, etc.

    According to Beroe's report, some of the widely used biomarkers for CVD as an integrated diagnostic approach include: CK ' MB Troponin I and T Myoglobin BNPs IMA

    Following the insights from Beroe's analysis, it can be said that the market is moving more towards global as: Regional engagement requires revalidation in secondary labs The local engagement has difficulty while developing complex biomarkers

    The key suppliers include the following names: Covance QPS Immune Health SGS Charles River PRAHS

    The global market size of biomarkers is nearly $29 Bn which grows at a CAGR rate of 13 ' 14 percent.

    The four restraints that are hampering biomarkers procurement for the corporates are: High capital investment and low cost-benefit ratio Poorly suited regulatory and reimbursement systems Technical issues related to sample collection and storage Government regulation and ethical problems Complex process

    Biomarkers market report transcript


    Global Market Outlook on Biomarkers

    The market growth is mainly driven by factors, such as increasing diagnostic applications of biomarkers, rise in R&D funding from the government, growing number of CROs, low cost of clinical trials in the developing countries, high prevalence and incidence of chronic diseases, and new initiatives for biomarker research

    • Biomarkers are important for predicting prognosis and selecting dose regimes. They are helpful for detecting therapeutic advances and adverse responses as well as for patient stratification, based on efficacy or safety prediction
    • Biomarkers are essential tools for the selection of appropriate patients for treatment with certain drugs, and so enables personalized medicine to a greater extent
    • Biomarker information is also included in labelling, in case of negative selection (i.e., if the biomarker is used to select a population unlikely to respond) or in case of uncertainty about the value of the biomarker, but where a negative selection is suspected, e.g., vandetani
    • Genomics-based biomarker platform is the fastest growing and heavily adopted technology among others. In fact, the genomics biomarker market is expected to grow at a CAGR of ~25–26 percent in the next five years
    • Proteomics biomarker discovery, albeit more complex, is expected to grow at a CAGR of 12–14 percent
    • Imaging biomarkers are expected to grow at a steady rate of 14–15 percent over the next five years
    • The omics family is constantly growing and adding new members, such as genomics, proteomics, peptidomics, and the newer ones, such as epigenomics, transcriptomics, metabolomics, lipidomics, pharmacogenomics, interactomics, and chronemics

    Biomarker Market

    Cancer

    • The cancer biomarker market is expected to grow at a CAGR of 15 to 15.5 percent
      The market share of cancer biomarkers is expected to reach $ 32,632.11 million by 2024

    The growth factors include:

    –Increasing rate of cancer patients

    –Technological advancement of omics

    –Need for personalized cancer treatments

    –Rise in the government funding for cancer research

    • Among the regions, Asia–Pacific will continue to grow in the next five years

    Cardiovascular

    • Cardiovascular disorders is expected to grow at the highest CAGR of 15.9 percent and is expected to reach $ 25,063.53 million by 2024
    • Cardiac biomarkers are used as risk stratification for various CVDs, such as myocardial infraction, congestive heart failure, ACS, etc.
    • Some of the widely used biomarkers for CVDs as an integrated diagnostic approach include CK-MB, troponin I and T, myoglobin, BNPs, and IMA

    Drivers and Restraints

    Drivers

    • Increasing diagnostic applications of biomarkers

    −Personalized medicine, an emerging practice of medicine that uses an individual's enetic profile to guide decisions made, in regard to the diagnosis, prevention, and treatment of diseases.

    −Companion diagnostics involves the use of biomarkers that provides biological and/or clinical information that enables better decision making about the development and use of a potential drug therapy

    • Increasing R&D funding for pharma and biotech companies
    • Non-invasive biomarkers can help in decision making during interim analysis in protocols
    • Accuracy in result - Biomarkers can also reflect the entire spectrum of disease from the earliest manifestations to the terminal stages
    • Increasing number of CROs and low cost of clinical trials in developing countries
    • Multi-marker Application: Combination of markers used in the care, along the entire spectrum of disease, by improving screening, simplifying diagnosis, clarifying prognosis, and tailoring treatment
    • Gene-level diagnosis: Cancer diagnosis is becoming more easier with the incorporation of molecular markers, such as DNA, RNA, micro RNAs, and proteins

    Restraints

    • High capital investment and low cost-benefit ratio
    • Poorly suited regulatory and reimbursement systems
    • Technical issues related to sample collection and storage
    • Government regulation and ethical problems
    • Complex process